Accelerating Medicines Partnership® SCHIZOPHRENIA


The Accelerating Medicines Partnership (AMP®) program is a public-private partnership between the National Institutes of Health, the U.S. Food and Drug Administration, the European Medicines Agency, pharmaceutical and life science companies, non-profit and other organizations. The AMP Schizophrenia (SCZ) program was launched in 2020 to address the critical need for more effective treatments for people with schizophrenia and related mental health conditions.

Read More

Study Sites

The AMP SCZ program consists of a coordination center and two research networks of 43 study sites across the globe.

Explore Locations
Study sites map

Frequently Asked Questions

If you or a family member has been invited to participate in this study, you probably have lots of questions. Review our frequently asked questions to get the answers you are looking for.

What is clinical research? What are some reasons to participate in research? I don't have schizophrenia. Can I still participate? What happens after the study? Read More